119results about How to "Induced death" patented technology

This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly FGFR2 variants, which are linked to drug resistance. The disclosure further provides methods of diagnosis and theranosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.

The invention provides compounds and compositions useful for the modulation of certain enzymes. The compounds and compositions can induce of cell death, particularly cancer cell death. The invention also provides methods for the synthesis and use of the compounds and compositions, including the use of compounds and compositions in therapy for the treatment of cancer and selective induction of apoptosis in cells.

In accordance with one aspect of the present invention, methods have been developed for identifying compositions which support the culture of defined cell populations. In accordance with another aspect of the present invention, methods have been developed for identifying compositions which promote differentiation of defined cell populations. In accordance with yet another aspect of the present invention, methods have been developed for identifying compositions which induce apoptosis of defined cell populations. In accordance with still another aspect of the present invention, methods have been developed for identifying compositions which promote cell senescence of defined cell populations. In accordance with still another aspect of the present invention, methods have been developed for identifying media which modulate the retardation of cell growth of defined cell subpopulation(s). In accordance with further aspects of the present invention, there are provided novel compositions identified by invention methods. Also provided are various uses of the novel compositions identified by invention methods, and novel cell populations produced employing same. In accordance with still another aspect of the present invention, methods have been developed for identifying compositions which support the culture of aberrant cell populations. In accordance with yet another aspect of the present invention, methods have been developed for identifying compositions which promote differentiation of aberrant cell populations. In accordance with still another aspect of the present invention, methods have been developed for identifying compositions which induce apoptosis of aberrant cell populations.

The present invention relates to a compound of formula (I):

or a pharmaceutically acceptable salt thereof, wherein R¹-R⁴, Q, Z, r, and p are as defined herein. Compounds of the present invention are useful in the treatment of diseases associated with FAK overexpression, including proliferative diseases.

Methods of using compounds having certain inhibitory effect to treat cancer are disclosed. More specifically, methods of using myosin light chain kinase inhibitor (MLCK) to treat cancer are disclosed. MLCK inhibitors may cause reduction in MLC-P and induce apoptosis in neoplastic cells and prevent and or inhibit the tumor growth.

This invention relates to anti-cancer compounds and to methods for treating or preventing cancer. In one aspect the invention concerns mitochondrially delivered pro-oxidant anti-cancer compounds that generate reactive oxygen species and induce apoptosis of cancerous cells. The delivery moiety can be a lipophilic cation and the pro-oxidant vitamin E analogue, such as α-tocopheryl succinate, α-tocopheryl maleate, α-tocopheryl maleyl amide, or 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)-chroman-6-yloxyacetic acid (α-tocopheryloxyacetic acid).

An agent for inducing cell death and/or inhibiting cell growth for cancer cells. The agents of the present invention comprise, as active ingredients, a drug inhibiting GST-π and a drug inhibiting a homeostasis-related protein that exhibits synthetic lethality when inhibited together with GST-π. The homeostasis-related protein can be a cell cycle-regulating protein or an anti-apoptosis-related protein.

The described invention provides small molecule anti-cancer compounds that selectively target and inhibit measurable biological activity of truncated APC proteins, an immortalized Human Colonic Epithelial Cell (HCEC) model, and pharmaceutical compositions comprising at least one of the small molecule anti-cancer compounds and a pharmaceutically acceptable carrier.

Disclosed are pharmaceutical compositions for inducing an immune response against tumor cells comprising tumor cells which are made apoptotic by treatment with high hydrostatic pressure and dendritic cells, and methods for producing such compositions.

Methods for detecting antibody dependent cellular cytotoxicity (ADCC) are described herein. The methods are label-free, and can be performed in real time on adherent cells. The methods can include, for example, (a) monitoring the impedance between electrodes on a non-conducting substrate that supports the growth of target cells in an assay medium; and (b) adding effector cells and an antibody that binds to the target cells to the assay medium; wherein any decrease in the impedance between the electrodes on the substrate following addition of the effector cells and the antibody is indicative of ADCC function having been effected in the assay medium.

The present invention provides materials and methods to induce cell death by methuosis, a non-apoptotic cell death mechanism, to induce vacuolization without cell death, or to induce cell death without vacuolization. Small molecules herein are useful for treating cell proliferation disorders or anomalies, particularly, but not exclusively, cancer. Methods related to the research and pharmaceutical use of the small molecules are also provided herein.

The invention discloses curcumin-containing aryl metal complexes which can effectively improve bioavailability of curcumin and have good phototoxicity, anti-cancer activity, angiogenesis inhibiting capacity and antibacterial activity. The invention further discloses a synthetic method of the curcumin-containing aryl metal complexes. The method adopts simple technical process, is easy to operate and high in yield. The invention finally discloses an application of the curcumin-containing aryl metal complexes to preparation of anti-cancer drugs, anti-cancer drug components, anti-tumor metastasisdrugs, anti-tumor metastasis drug components, antibacterial agents and antibacterial agent components.

The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., multiple myeloma). It relates to anti-CD56 antibodies, chimeric antigen receptors (CARs) that specifically target human CD56, and immunoresponsive cells comprising such CARs. The presently disclosed CD56-specific CARs have enhanced immune-activating properties, including anti-tumor activity.

The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods the use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.

The present invention provides a drug capable of causing cancer cells to restore anticancer drug sensitivity in cases in which cancer has acquired resistance to an anticancer drug and inducing cell death in cancer cells. The present invention specifically provides a cancer cell death inducing agent comprising REIC/Dkk-3 DNA as an active ingredient and having effects of potentiating an anticancer drug for cancer cells having anticancer drug resistance.

Provided in the present invention are a YAP protein inhibiting polypeptide and application thereof. In particular, the present invention obtains a key binding site of YAP protein and TEAD, screens a polypeptide with best YAP inhibitory activity and modifies the polypeptide, such as adding a disulfide linkage, replacing an amino acid, removing and/or adding (for example, adding a cell-penetrating element), and finally screens and verifies the obtaining of a series of polypeptides with YAP protein activity inhibiting effect and good stability. Experiments show that the polypeptide of the present invention can effectively inhibit the binding activity between YAP protein and TEAD, thus providing good therapeutic effect on digestive tract tumors (especially liver cancer).